EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 105 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Sugar and cancer – what you need to know October 20, 2020 Registered Dietitian vs. Nutritionist March 3, 2021 Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer April 27, 2018 ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current... May 19, 2021 Load more HOT NEWS After 5 Years of Follow-Up, the Median PFS Has Yet To... Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery Anal Cancer Incidence and Deaths Are Rising in the United States People with Intellectual Disability at Increased Risk of Cancer
